Read by QxMD icon Read

Chronic spontaneous urticaria

Sahar Z Elazab, Waheed F Hessam
Chronic spontaneous urticaria (CSU) is a common distressing disease caused mainly by autoreactive mechanisms. Autologous serum therapy (AST) has been tried for treatment of many autoimmune diseases including chronic urticaria. We assessed the effect of AST in autologous serum skin test (ASST)-positive and ASST-negative CSU patients. The study included 40 patients clinically diagnosed as CSU. Twenty ASST-positive patients and 20 ASST-negative patients received AST for 8 weeks. Urticarial activity was assessed at baseline, 4th week, 9th week, and at the 12th week by the weekly urticarial activity score (UAS-7) according to the EAACI/GA2LEN/EDF/WAO guidelines...
June 2017: Egyptian Journal of Immunology
Shekhar Neema, Manas Chatterjee
Aim: To study the effects of omalizumab in chronic spontaneous urticaria in Indian patients. Setting and Design: The study was conducted in a tertiary care centre and it was retrospective and descriptive in nature. Material and Methods: We analysed the data of patients who were administered omalizumab between June 2014 and June 2015 for the management of refractory chronic spontaneous urticaria at our centre. Omalizumab was used in those patients who did not respond to updosing of antihistaminics and cyclosporine...
January 2018: Indian Journal of Dermatology
Gustavo Deza, Marta Bertolín-Colilla, Silvia Sánchez, Dulce Soto, Ramon M Pujol, Ramon Gimeno, Ana M Giménez-Arnau
This study suggests that baseline levels of basophil FcεRI receptor may predict time to response to anti-IgE therapy in chronic spontaneous urticaria.
March 5, 2018: Journal of Allergy and Clinical Immunology
(no author information available yet)
BACKGROUND: Chronic idiopathic urticaria (CIU)/spontaneous urticaria (CSU) is defined by the presence of wheals,angioedema, or both for 6 weeks, with or without an identifiable trigger. Real-world health care data among children withCIU/CSU remain scarce. OBJECTIVES: To describe treatment patterns, health care resource utilization (HRU), and costs in pediatric patients with CIU/CSU (12 years old) and to compare these with pediatric patients without CIU/CSU. METHODS: A commercial administrative claims data base (September 2013 to June 2016) was used...
March 7, 2018: Allergy and Asthma Proceedings:
Eustachio Nettis, Luca Cegolon, Elisabetta Di Leo, Walter Giorgio Canonica, Aikaterini Detoraki
BACKGROUND: Omalizumab therapy is effective and safe in patients with chronic spontaneous urticaria (CSU) resistant to nonsedating histamine1 (H1 ) antihistamines (nsAHs). OBJECTIVE: To evaluate the efficacy and safety of omalizumab in elderly (aged ≥65 years) patients with nonsedating H1 -antihistamine-refractory CSU in a real-life setting. METHODS: Patients with nonsedating H1 -antihistamine-refractory CSU (n = 322) treated with omalizumab administered every 4 weeks in doses of 300 mg for 24 weeks were divided into 2 groups according to age at omalizumab treatment onset: 15 to 64 years and 65 years or older...
March 2018: Annals of Allergy, Asthma & Immunology
Eustachio Nettis, Maria Distaso, Salvatore Saitta, Marco Casciaro, Mariateresa Cristani, Antonina Saija, Angelo Vacca, Sebastiano Gangemi, Paola L Minciullo
Introduction: Oxidative stress is a result of an imbalance between endogenous production of free reactive oxygen species and reduced effectiveness of antioxidant defence mechanisms. Advanced glycation end products (AGEs) and advanced oxidation protein products (AOPPs) are compounds formed by transformation of macromolecules, including proteins which can serve as markers of oxidative stress and inflammation in several diseases. Aim: To investigate the role of AGEs and AOPPs as new markers of oxidative stress and inflammation in patients with chronic spontaneous urticaria (CSU)...
October 2017: Postȩpy Dermatologii i Alergologii
Eli Magen, Tinatin Chikovani, Dan-Andrei Waitman, Natan R Kahan
BACKGROUND: Epidemiologic studies report that alopecia areata (AA) is related to various atopic and autoimmune diseases. The purpose of this study was to identify clinical characteristics and the prevalence of comorbid conditions in Israeli patients with AA. METHODS: This retrospective, matched, case-control study was based on data from an electronic patient record data base. The patients with an electronically documented diagnosis of AA were included in the AA group...
March 1, 2018: Allergy and Asthma Proceedings:
J Marcelino, A C Costa, A Mendes, E Alonso, F Cabral Duarte, E Pedro, M Pereira-Barbosa
Objective. Describe the safety and long-term use of omalizumab in chronic urticaria (CU), both spontaneous (CSU) and inducible (CIndU). Methods. Retrospective chart-review (2006-15) of CU patients treated with omalizumab for ≥ 6 months. Statistical analyses: descriptive statistics, Mann-Whitney, generalized linear models. Results. 23 patients with CSU (3 men), 3 with CIndU (2 men). Generalized linear models showed UAS reduction per omalizumab administration of 16% in CIndU and CSU and UAS7, of 15% in CIndU, and 20% in CSU...
January 16, 2018: European Annals of Allergy and Clinical Immunology
T A Kanters, H B Thio, L Hakkaart
BACKGROUND: Chronic spontaneous urticaria (CSU) is a skin disease, with itchy hives and / or angioedema that last for at least 6 weeks without an obvious external trigger. OBJECTIVES: The objective of this study was to determine the cost-effectiveness of omalizumab relative to standard of care (SoC; up to 4 times the daily dose of H1-antihistaminics) for the Netherlands from a societal perspective. METHODS: The Markov model used consisted of five health states based on Urticaria Activity Score over seven days (UAS7)...
February 24, 2018: British Journal of Dermatology
Gordon Sussman, Mohamed Abuzakouk, Frédéric Bérard, Walter Canonica, Hanneke Oude Elberink, Ana Giménez-Arnau, Clive Grattan, Kelly Hollis, Shannon Hunter, André Knulst, Jean-Philippe Lacour, Charles Lynde, Alexander Marsland, Doreen McBride, Marcus Maurer, Alla Nakonechna, Javier Ortiz de Frutos, Maria Reynolds, Carolyn Sweeney, Haijun Tian, Karsten Weller, Daniel Wolin, Maria-Magdalena Balp
BACKGROUND: ASSURE-CSU revealed differences in physician and patient reporting of angioedema. This post-hoc analysis was conducted to evaluate the actual rate of angioedema in the study population and explore differences between patients with and without angioedema. METHODS: This international observational study assessed 673 patients with inadequately controlled chronic spontaneous urticaria (CSU). Physicians abstracted angioedema data from medical records, which were compared with patient-reported data...
February 20, 2018: Allergy
(no author information available yet)
BACKGROUND: Omalizumab was approved for the treatment of chronic idiopathic urticaria (CIU)/chronic spontaneous urticaria (CSU) in the United States in March 2014. OBJECTIVE: This study sought to describe real-world omalizumab use, in the United States, in a large cohort of patients withCIU/CSU. METHODS: Patients with CIU/CSU (ages greater than or equal to 12 years) initiated on omalizumab (index date) with greater than or equal to 12 months of pre- and postindex data were identified in the an insurance claims data base (January 1, 2013, to July 31, 2016)...
February 19, 2018: Allergy and Asthma Proceedings:
Jonathan A Bernstein, Abhishek Kavati, Michael D Tharp, Benjamin Ortiz, Karen MacDonald, Kris Denhaerynck, Ivo Abraham
Chronic idiopathic/spontaneous urticaria (CIU/CSU) is a dermatological condition characterized by itchy wheals and/or angioedema of continuous or intermittent duration of ≥6 weeks with a high burden of disease and impact on quality of life. Omalizumab is a recombinant humanized monoclonal antibody that inhibits the binding of IgE to high affinity receptors, and is approved for the CIU/CSU indication. The objective of this systematic review was to evaluate and synthesize the evidence on the real-world effectiveness of omalizumab in CIU/CSU in daily clinical practice...
February 12, 2018: Expert Opinion on Biological Therapy
Paul V Williams, Abhishek Kavati, Dominic Pilon, Yongling Xiao, Maryia Zhdanava, Maria-Magdalena Balp, Patrick Lefebvre, Benjamin Ortiz, Vivian Hernandez-Trujillo
INTRODUCTION: Few studies have described chronic idiopathic/spontaneous urticaria (CIU/CSU) healthcare burden in adults, while this information remains largely unknown in children. We aimed to describe treatment patterns, healthcare resource utilization (HRU), and costs in CIU/CSU pediatric patients, as well as to compare HRU and costs in CIU/CSU and CIU/CSU-free pediatric patients. METHODS: Medicaid claims from four states (09/01/2013-03/31/2016) were used to identify patients less than 12 years old...
February 10, 2018: Dermatology and Therapy
Magdalena Czarnecka-Operacz, Anna Sadowska-Przytocka, Dorota Jenerowicz, Anna Szeliga, Zygmunt Adamski, Katarzyna Łącka
Introduction: Chronic urticaria (CU) is a skin disease caused by autoantibodies against high affinity immunoglobulin E (IgE) receptor and against IgE. It is characterized by hives, erythematous wheals and redness present minimum twice a week for at least 6 weeks. It is observed that there is a strong association between CU and autoimmune diseases, such as autoimmune thyroiditis (AT). Aim: To verify the frequency of AT in patients suffering from chronic spontaneous urticaria (CSU) and to confirm the coexistence of CU and AT in the Polish population...
December 2017: Postȩpy Dermatologii i Alergologii
Hye Jung Park, Kyung Soo Suk, Jung Won Park
Intraoperative bovine-derived topical thrombin is still widely used for hemostasis during surgery. A 38-year-old woman with chronic spontaneous urticaria was referred to the orthopedic surgery department for herniated disk and myelopathy. During the first stage of operation, bovine-derived thrombin powder soaked in Gelfoam was used as a hemostatic aid. After 30 minutes, the patient developed anaphylactic shock with systemic skin rash and angioedema. Repeated intravenous bolus and infusion of vasopressor were carried out, and her blood pressure normalized...
March 2018: Allergy, Asthma & Immunology Research
Nikolaos Syrigos, Dimitra Grapsa, Maria Zande, Marianna Tziotou, Ekaterini Syrigou
BACKGROUND: Previous clinical trials have demonstrated the efficacy and safety of the anti-IgE monoclonal antibody omalizumab in chronic spontaneous urticaria (CSU) not responding to antihistamine treatment. The primary aim of our study was to describe the response patterns of patients with refractory CSU treated with omalizumab in a real-world clinical setting. METHODS: A retrospective analysis of medical records of 20 patients with refractory CSU was performed...
February 5, 2018: International Journal of Dermatology
Mona Al-Ahmad, Tito Rodriguez-Bouza, Midhat Nurkic
BACKGROUND: A history of nonsteroidal anti-inflammatory drug (NSAID) hypersensitivity with cross-intolerance to several drugs is common in some patients with coronary artery disease. We present a series of patients with acute coronary syndrome undergoing ASA desensitization prior to a possible stent to evaluate the short- and long-term efficacy and safety. The aim was to evaluate the outcomes of an ASA desensitization protocol developed by our center based on the guidelines proposed by the EAACI drug allergy expert recommendations...
January 26, 2018: International Archives of Allergy and Immunology
Hélène Cornillier, Bruno Giraudeau, Stéphane Munck, Florence Hacard, Annie-Pierre Jonville-Bera, Gwenaëlle d'Acremont, Bach-Nga Pham, Annabel Maruani
BACKGROUND: Chronic spontaneous urticaria (CSU) is not frequent in children. Management guidelines have been developed for adults and randomized controlled trials (RCTs) included teenagers aged 12 to 18, but data for children under age 12 are limited. We performed a systematic review to assess comorbidities in children < 12 years old with CSU and the efficacy and safety of treatments. METHODS: We searched for original articles of epidemiologic and treatment data in children < 12 years old with CSU that were published from 2005 to July 2016 in MEDLINE, EMBASE, CENTRAL and LILACS...
February 2, 2018: Pediatric Allergy and Immunology
R Asero
Up to 30% of cases of chronic spontaneous urticaria (CSU) are exacerbated by COX-1 inhibit-ing nonsteroidal anti-inflammatory drugs (NSAID); this clinical picture is termed NECD (NSAID-exacerbated cutaneous disease). On the other hand, multiple NSAID hypersensitivity may occur in the absence of an underlying CSU also, a situation that is termed NIUA (NSAID-induced urticaria / angioedema). The present study reports a case of multiple NSAID hypersensitivity that occurred in a man much before he developed severe CSU...
November 30, 2017: European Annals of Allergy and Clinical Immunology
Charoen Choonhakarn, Suteeraporn Chaowattanapanit, Narachai Julanon
BACKGROUND: An increase in dosages up to fourfold of second generation antihistamines is recommended for recalcitrant chronic spontaneous urticaria (CSU). No regimen guidelines about dose de-escalation, however, are mentioned once the disease is controlled. OBJECTIVE: To demonstrate the treatment outcomes and dose reduction in desloratadine assessed using the urticarial activity score over 7 consecutive days. METHODS: Medical records of all patients with CSU treated with desloratadine were collected retrospectively during a period from January 2010 to December 2013...
January 30, 2018: International Journal of Dermatology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"